What Current Reports Say About Tysabri and PML Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Specific Exposure Risks

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This page reviews documented reports on PML risk factors and long-term outlook. Building on a tradition of translating complex biomedical research into accessible guidance, we provide a focused overview of what current evidence says about monitoring and risk management.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently placed to alert healthcare professionals and patients to the serious nature of this adverse event. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, weighing expected benefits against the risk of PML. PML typically presents with progressive neurological deficits. Common symptoms include cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The condition usually leads to severe disability or death, as noted in the boxed warning. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks lymphocyte migration into the central nervous system, which reduces immune surveillance. This immunosuppressive effect allows reactivation of latent JC virus in the brain, leading to lytic infection of oligodendrocytes and subsequent demyelination. The risk is highest in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus. FDA adverse event reports frequently list neurological symptoms associated with Tysabri use. Among the most common reports are fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), and balance disorder (5,621 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms can overlap with PML presentation, making early diagnosis challenging.

Legal Considerations and Statute of Limitations in Ohio

The adequacy of warnings regarding Tysabri and PML is a central issue in legal considerations. The boxed warning clearly states the risk, but questions may arise about whether patients were adequately informed about the specific risk factors and the need for monitoring. The prescribing information instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Failure to follow these monitoring guidelines could be relevant in legal claims. For patients in Ohio, the statute of limitations for filing a product liability lawsuit related to Tysabri and PML is generally two years from the date the injury was discovered or should have been discovered. This discovery rule means the clock starts when the patient knew or reasonably should have known that Tysabri caused their PML. Given that PML symptoms can develop gradually and mimic multiple sclerosis relapses, the date of discovery may be when a definitive diagnosis is made via MRI and JC virus testing. The timeline between Tysabri exposure and documented harm is variable. PML risk increases with longer treatment duration, especially beyond two years. However, cases have been reported after shorter exposure, particularly in patients with additional risk factors. The latency period from initial Tysabri infusion to PML symptom onset can range from months to several years. Attorney-related considerations for affected patients include the need to preserve medical records documenting Tysabri treatment dates, dosing, and any monitoring performed. Records of anti-JCV antibody testing, MRI results, and PML diagnosis are essential. Patients should also document any communications with healthcare providers about PML risks and symptoms. In summary, the medical evidence clearly establishes that Tysabri increases PML risk, with specific risk factors identified. The drug's labeling includes a boxed warning and monitoring instructions. For Ohio patients, the two-year statute of limitations from discovery of the injury applies. Legal consultation is advisable to evaluate individual circumstances and ensure timely filing of any claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Ohio?

In Ohio, the statute of limitations for filing a product liability lawsuit related to Tysabri and PML is generally two years from the date the injury was discovered or should have been discovered. This discovery rule means the clock starts when the patient knew or reasonably should have known that Tysabri caused their PML.

What are the key risk factors for developing PML while on Tysabri?

Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.